BTK in­hibitors from As­traZeneca, Eli Lil­ly and BeiGene take cen­ter stage in CLL

SAN DIEGO — Some of the biggest names in BTK in­hibitors pre­sent­ed up­dat­ed datasets at the Amer­i­can So­ci­ety of Hema­tol­ogy an­nu­al meet­ing this week­end, most …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER